Patient-Reported Outcomes for Cancer Patients with Hematological Malignancies Undergoing Chimeric Antigen Receptor T Cell Therapy: A Systematic Review

Mona Kamal, Jacinth Joseph, Uri Greenbaum, Rachel Hicklen, Partow Kebriaei, Samer A. Srour, Xin Shelly Wang

Research output: Contribution to journalReview articlepeer-review

15 Scopus citations

Abstract

Databases were searched to identify studies published over the past 10 years that addressed the utility of patient-reported outcomes (PROs) in patients receiving chimeric antigen receptor (CAR) T cell therapy in patients with hematological malignancies. Among 280 records, three articles covering 206 patients were eligible. The data were prospectively collected at multiple time points. The compliance rates were 70% to 94%. There was an inverse relationship between fatigue and social function among adults. The quality of life (QoL) improvement and ability to complete PROs were linked to disease status. About 40% of adults reported at least some cognitive difficulties, with a detrimental impact on mental and physical health status. In adults, the most commonly reported cognitive impairment was memory difficulties. Depression was associated with cognitive difficulties. Younger adults were at higher risk of long-term poor mental health, anxiety, and depression. For pediatric and adolescent patients, emotional dysfunction improves over time. QoL status improved over time; yet, severe cytokine release syndrome and neurotoxicity caused delayed improvement. Information regarding whether the PROs were integrated into medical records and clinical guidelines is lacking. Utilizing PROs in patients on CAR T cell therapy seems feasible and informative. Studies utilizing larger sample sizes and using validated PRO tools at different time points remain unmet needs.

Original languageEnglish (US)
Pages (from-to)390.e1-390.e7
JournalTransplantation and Cellular Therapy
Volume27
Issue number5
DOIs
StatePublished - May 2021

Keywords

  • CAR T cell therapy
  • Cancer
  • Hematological malignancies
  • Patient-reported outcomes
  • Quality of life
  • Systematic review

ASJC Scopus subject areas

  • Hematology
  • Transplantation
  • Immunology and Allergy
  • Cell Biology
  • Molecular Medicine
  • General Medicine

Fingerprint

Dive into the research topics of 'Patient-Reported Outcomes for Cancer Patients with Hematological Malignancies Undergoing Chimeric Antigen Receptor T Cell Therapy: A Systematic Review'. Together they form a unique fingerprint.

Cite this